Company had 3.7 million in the bank as at 31st September
+
12.5 million from this new CR
Total shares will be around 836 million
That is cash backing of 0.019
So if it goes back to 0.05 as some are suggesting the market value of those drugs in different stages of trial are valued at 0.03 ?
Provided world's one of the largest pharma is doing partnership agreement with PAB there is a potential for its durg..and in the case of success with AMGEN I think PAB will be a TO target
Company had 3.7 million in the bank as at 31st September+12.5...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
